Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease.
Giulio CavalliAlessandro TomelleriGiacomo De LucaCorrado CampochiaroCharles A DinarelloElena BaldisseraLorenzo DagnaPublished in: Arthritis research & therapy (2019)
Keyphrases